A two-phased, randomized, double blind, placebo-controlled study of ECP002A (Δ9-THC) to determine safety, tolerability and efficacy in multiple sclerosis patients suffering from spasticity and pain

Category Primary study
Year 2010
This article has no abstract
Epistemonikos ID: af4046fbc88a7302b2962096944f2c08507f8193
First added on: Apr 01, 2023